Preparation method of tafluprost impurity

The three-step synthesis method for preparing tafluprost impurities solves the problem of impurities affecting drug purity, achieves the preparation of high-purity impurities, simplifies the operation and reduces costs, and is suitable for the quality control of tafluprost drugs.

CN118908925AInactive Publication Date: 2024-11-08QUALITY CONTROL SOLUTIONS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410924813.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the existing technology, impurities exist in tafluprost drugs, affecting drug purity and safety, and there is a lack of effective methods for preparing these impurities.

Method used

A three-step synthesis method was adopted, which includes adding the substrate to different organic solvents and stirring the reaction, preparing tafluprost impurities through intermediate protection and specific nucleophilic reactions, using non-toxic and readily available solvents and reaction conditions, and simplifying the purification process.

Benefits of technology

The prepared tafluprost has high impurity purity, meets the requirements of standard products, and is suitable for qualitative and quantitative studies, thus improving the reliability and safety of drug quality control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908925A_ABST
    Figure CN118908925A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a tafluprost impurity, which comprises the following steps: step I, adding a substrate 3 into an organic solvent 1 of a raw material 1, stirring for reaction, dropwise adding a substrate 2 at low temperature, and stirring at room temperature; step II, sequentially adding a substrate 5 and a substrate 7 into the organic solvent of the raw material 4, stirring for reaction, then adding a substrate 6, and stirring at room temperature overnight; step III, adding a substrate 9 into the mixed solvent III of the raw material 8, and stirring for reaction to obtain a target product 10; the invention relates to the technical field of medicine impurity synthesis. The preparation method of the tafluprost impurity has the advantages of simple operation, short preparation period, low cost and environmental protection, and the prepared tafluprost impurity has high purity and no obvious impurity points, meets the requirements of impurity reference substances, can be used as a tafluprost impurity standard substance to be applied to qualitative and quantitative research and detection of the tafluprost impurity, and has wide application prospects. And the method has certain significance on quality control of tafluprost raw material medicines and related preparations thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug impurity synthesis, in particular to a method for preparing tafluprost impurities. Background Art

[0002] Tafluprost, chemical name (3aR, 4S, 5S, 6aS)-4-(hydroxymethyl)-2-oxohexahydro-2H-cyclopenta[b]furan-5-ylbenzoate, is a colorless to light yellow viscous liquid with a chemical formula of C15H16O5, a molecular weight of 276.288, and a chemical structural formula of It is a prostaglandin analogue and a selective FP prostaglandin receptor agonist. It can reduce intraocular pressure by increasing the outflow of aqueous humor through the uveal and scleral pathways. It is mainly used to reduce open-angle glaucoma and ocular hypertension. Tafluprost is a new type of PGF2a biologic. It is superior to the known natural PGF2ax in terms of peak intraocular pressure reduction. It has little irritation to the eye and has little effect on ocular tissues such as the cornea, iris, and conjunctiva. It has long-lasting effects. They are characterized by much less melanin production and longer efficacy compared to other drugs. The drug was developed by Santen Pharmaceutical in Japan and was approved in Japan in October 2008, approved by the FDA in February 2012, and entered China in July 2015. The trade name is Tapros. The drug is used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The latest studies show that this product can effectively reduce high intraocular pressure in glaucoma patients, and is highly safe and well tolerated. In May 2015, it was approved by CFDA for clinical trials.

[0003] The quality of drugs is an important criterion for measuring drug quality. Impurities are the main factor affecting drug purity. They exist as control samples for impurities to be studied in drug molecular mass research. If the drug contains impurities exceeding the limit, it may cause changes in physical and chemical constants, variations in appearance, and affect the stability of the drug. The increase in impurities will inevitably lead to lower drug content or reduced activity, and significantly increased toxic and side effects. Therefore, drug impurity inspection is a very important link in controlling drug purity and improving drug quality.

[0004] This patent synthesizes an impurity of tafluprost, the presence of which may affect the effectiveness and safety of tafluprost API and its preparations. Therefore, the preparation and research of this impurity is of great significance to the process research and quality control of tafluprost API and its preparations. Summary of the invention

[0005] 1. Technical issues to be resolved

[0006] In view of the deficiencies of the prior art, the present invention provides a method for preparing tafluprost impurities, which solves the problems mentioned in the above background technology.

[0007] (II) Technical solution

[0008] To achieve the above object, the present invention is implemented by the following technical scheme: a method for preparing tafluprost impurities, comprising the following steps:

[0009] Step I: Add substrate 3 to the organic solvent 1 of raw material 1, stir to react, add substrate 2 dropwise at low temperature, stir at room temperature, the reaction formula is as follows:

[0010]

[0011] Step II: Add substrate 5 and substrate 7 to the organic solvent of raw material 4 in sequence, stir to react, then add substrate 6, stir at room temperature overnight, the reaction formula is as follows:

[0012]

[0013] Step III: Add substrate 9 to the mixed solvent III of raw material 8, stir and react to obtain target product 10. The reaction formula is as follows:

[0014]

[0015] Preferably, in step I, stirring is carried out at room temperature for 30 minutes.

[0016] Preferably, in step II, stirring is carried out at room temperature for 10 minutes.

[0017] Preferably, in step III, stirring is carried out at room temperature for 30 minutes.

[0018] Preferably, in step I, the organic solvent 1 is a dichloromethane solution.

[0019] Preferably, in step II, the second organic solvent is a tetrahydrofuran solution.

[0020] Preferably, in step III, the organic solvent three is a mixed solution of methanol: water: ammonia water.

[0021] (III) Beneficial effects

[0022] The invention provides a method for preparing tafluprost impurities. Compared with the prior art, the method has the following beneficial effects: the method for preparing tafluprost impurities has the advantages of simple operation, short preparation cycle, low cost and environmental protection, the prepared tafluprost impurities have high purity, no obvious impurity points, meet the requirements of impurity reference substances, can be used as tafluprost impurity standard substances for qualitative and quantitative research and detection of tafluprost impurities, and has certain significance for the quality control of tafluprost raw materials and related preparations. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 A hydrogen spectrum of a target product provided in a method for preparing a tafluprost impurity of the present invention;

[0024] Figure 2 A carbon spectrum of a target product provided in a method for preparing a tafluprost impurity of the present invention;

[0025] Figure 3 A mass spectrum of a target product provided by a method for preparing a tafluprost impurity of the present invention;

[0026] Figure 4 A liquid phase spectrum of a target product provided for a method for preparing a tafluprost impurity of the present invention. DETAILED DESCRIPTION

[0027] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] The embodiment of the present invention provides the following technical solutions:

[0029] Example 1: Preparation of raw material 4: 6.00 g of raw material 1 was dissolved in 100 mL of dichloromethane solution, and then 10.00 ml of substrate 3 was added, and stirred at room temperature for 30 minutes, and then 5.00 mL of substrate 2 was added dropwise at low temperature and stirred at room temperature. The reaction formula is as follows:

[0030]

[0031] The reaction was monitored by TLC chromatography (developing solvents were petroleum ether and ethyl acetate, and the mass ratio of petroleum ether to ethyl acetate was 2:1) until the reaction was completed, saturated sodium bicarbonate solution (50.00 mL) was added to the reaction system to quench the reaction, ethyl acetate (150.00 mL) was added to dilute and transferred to a separatory funnel, washed with water (100.00 mL) twice, washed with saturated brine (100.00 mL) once, the aqueous layer was removed, the organic layer was collected, and dried with anhydrous sodium sulfate, filtered, and the filtrate was distilled under reduced pressure to remove the organic solvent to obtain a crude product; column chromatography separation and purification (eluents were petroleum ether and ethyl acetate, and the mass ratio of petroleum ether to ethyl acetate was 2:1) was used to obtain a white solid compound, wherein the mass of the white solid compound was 8.0 g, and the yield was 98%.

[0032] Example 2: Preparation of raw material 8: 8.00 g of raw material 4 was dissolved in 100 mL of tetrahydrofuran solution, and then 7.60 g of substrate 5 and 10.22 g of substrate 7 were added in sequence, and stirred at room temperature for 10 minutes, and then 6.79 g of substrate 6 was added, and stirring was continued at room temperature overnight. The reaction formula is as follows:

[0033]

[0034] The reaction was monitored by TLC chromatography (developing solvents were petroleum ether and ethyl acetate, and the mass ratio of petroleum ether to ethyl acetate was 2:1) until the reaction was completed, saturated sodium bicarbonate solution (20.00 mL) was added to the reaction system to quench the reaction, ethyl acetate (150.00 mL) was added to dilute and transferred to a separatory funnel, washed with water (100.00 mL) twice, saturated brine (100.00 mL) once, the aqueous layer was removed, the organic layer was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was distilled under reduced pressure to remove the organic solvent to obtain a crude product; column chromatography separation and purification (eluents were petroleum ether and ethyl acetate, and the mass ratio of petroleum ether to ethyl acetate was 2:1) to obtain a colorless transparent oily compound, wherein the mass of the colorless transparent oily compound was 9.97 g, and the yield was 82%.

[0035] Example 3: Preparation of the target product: 6.50 g of the raw material 8 was dissolved in 100 mL of a mixed solution of methanol: water: ammonia water in a ratio of 1:1:0.1, and then 5.98 g of the substrate 9 was added. The reaction was stirred at room temperature for 30 minutes to finally obtain the target product 10. The reaction formula is as follows:

[0036]

[0037] The reaction was monitored by TLC chromatography (the developing solvent was petroleum ether and ethyl acetate, and the mass ratio of petroleum ether to ethyl acetate was 2:1) until the reaction was completed, ethyl acetate (150.00 mL) and water (200.00 mL) were added for extraction, the aqueous layer was removed, the organic layer was collected, and a white solid pure compound was obtained by column chromatography. The mass of the white solid pure compound was 3.70 g, and the yield was 73%.

[0038] In this technical scheme, (-)-coreyl actone diol is used as the starting material, and its two hydroxyls are protected by sulfonyl groups under the action of alkali (imidazole) to obtain an intermediate, and the intermediate undergoes a specific nucleophilic reaction with benzoic acid under the action of sodium iodide and magnesium hydroxide to flip the configuration to obtain another intermediate, and finally, the residual protective agent group is gently removed by magnesium powder under the conditions of a methanol: water: ammonia mixed solvent to obtain the final product tafluprost impurity compound, and the tafluprost impurity is synthesized for the first time in a total of three steps. The purification is simple in the synthesis process, the yield is high, and no highly toxic and explosive dangerous goods are used, which conforms to the modern environmental protection and sustainable development concepts, can provide convenience for the impurity analysis and research of tafluprost raw materials and preparations thereof, and provide a detection method and judgment basis for the production and drug safety of tafluprost. The technical solution is simple to operate, short in preparation cycle, low in cost and environmentally friendly; the prepared tafluprost has high impurity purity and no obvious impurity points, meets the requirements of impurity reference substances, can be used as a tafluprost impurity standard substance for qualitative and quantitative research and detection of tafluprost impurities, and has certain significance for the quality control of tafluprost raw materials and related preparations.

[0039] Meanwhile, the contents not described in detail in this specification belong to the prior art known to those skilled in the art.

[0040] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.

[0041] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for preparing tafluprost impurities, characterized in that: The following steps are involved: Step I: Add substrate 3 to the organic solvent 1 of raw material 1, stir to react, add substrate 2 dropwise at low temperature, stir at room temperature, the reaction formula is as follows: Step II: Add substrate 5 and substrate 7 to the organic solvent of raw material 4 in sequence, stir to react, then add substrate 6, stir at room temperature overnight, the reaction formula is as follows: Step III: Add substrate 9 to organic solvent 3 of raw material 8, stir and react to obtain target product 10. The reaction formula is as follows:

2. The method for preparing a tafluprost impurity according to claim 1, characterized in that: In the step I, stirring is performed at room temperature for 30 minutes.

3. The method for preparing a tafluprost impurity according to claim 1, characterized in that: In the step II, stirring is performed at room temperature for 10 minutes.

4. The method for preparing a tafluprost impurity according to claim 1, characterized in that: In the step III, stirring is performed at room temperature for 30 minutes.

5. The method for preparing a tafluprost impurity according to claim 1, characterized in that: In the step I, the first organic solvent is a dichloromethane solution.

6. The method for preparing a tafluprost impurity according to claim 1, characterized in that: In the step II, the second organic solvent is a tetrahydrofuran solution.

7. The method for preparing a tafluprost impurity according to claim 1, characterized in that: In the step III, the organic solvent three is a mixed solution of methanol: water: ammonia water.